AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diag...
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid
The treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said. The combination also improved progression-free survival to a median of 22.1 months compared to 16.6 months for those treated with bevacizumab alone, the companies said.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug useGlaxoSmithKline and AstraZeneca both reported trial results that will likely mak...
Baca lebih lajut »
Results of GSK and AstraZeneca trials may widen ovarian cancer drug useGlaxoSmithKline and AstraZeneca both reported trial results that will likely mak...
Baca lebih lajut »
I went through menopause before I turned 40: What women should know'And after the hysterectomy I was in full-on menopause with hot flashes, moods swings and weight gain.'
Baca lebih lajut »
Novartis says Kisqali boosts survival in breast cancer patientsNovartis said on Sunday that Kisqali helped women with advanced breast cancer af...
Baca lebih lajut »
Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: studyAbout 40% of patients who received a combination of Bristol-Myers Squibb Co&039...
Baca lebih lajut »
Free Apps & Extensions That Improve Productivity & LearningFind out how to make any curriculum more accessible and engaging through the use of learning tools for Chromebooks, iPads, Windows, and Macs
Baca lebih lajut »